HK1254954A1 - Lpt-723和免疫检查点抑制剂组合物及其治疗方法 - Google Patents

Lpt-723和免疫检查点抑制剂组合物及其治疗方法 Download PDF

Info

Publication number
HK1254954A1
HK1254954A1 HK18114058.0A HK18114058A HK1254954A1 HK 1254954 A1 HK1254954 A1 HK 1254954A1 HK 18114058 A HK18114058 A HK 18114058A HK 1254954 A1 HK1254954 A1 HK 1254954A1
Authority
HK
Hong Kong
Prior art keywords
methods
immune checkpoint
checkpoint inhibitor
lpt
treatment
Prior art date
Application number
HK18114058.0A
Other languages
English (en)
Chinese (zh)
Inventor
Saurabh Saha
Linping Zhang
Xiaoyan Michelle ZHANG
Original Assignee
Biomed Valley Discoveries, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomed Valley Discoveries, Inc. filed Critical Biomed Valley Discoveries, Inc.
Publication of HK1254954A1 publication Critical patent/HK1254954A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK18114058.0A 2015-06-29 2016-06-28 Lpt-723和免疫检查点抑制剂组合物及其治疗方法 HK1254954A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562186157P 2015-06-29 2015-06-29
US62/186,157 2015-06-29
PCT/US2016/039885 WO2017004079A1 (en) 2015-06-29 2016-06-28 Lpt-723 and immune checkpoint inhibitor combinations and methods of treatment

Publications (1)

Publication Number Publication Date
HK1254954A1 true HK1254954A1 (zh) 2019-08-02

Family

ID=57609068

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18114058.0A HK1254954A1 (zh) 2015-06-29 2016-06-28 Lpt-723和免疫检查点抑制剂组合物及其治疗方法

Country Status (5)

Country Link
US (4) US9861621B2 (https=)
EP (1) EP3313186A4 (https=)
JP (4) JP6786529B2 (https=)
HK (1) HK1254954A1 (https=)
WO (1) WO2017004079A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201322725D0 (en) 2013-12-20 2014-02-05 Immodulon Therapeutics Ltd Cancer therapy
US9861621B2 (en) * 2015-06-29 2018-01-09 Biomed Valley Discoveries, Inc. LPT-723 and immune checkpoint inhibitor combinations and methods of treatment
SG11201913137VA (en) 2017-07-11 2020-01-30 Compass Therapeutics Llc Agonist antibodies that bind human cd137 and uses thereof
WO2019089753A2 (en) 2017-10-31 2019-05-09 Compass Therapeutics Llc Cd137 antibodies and pd-1 antagonists and uses thereof
US11851497B2 (en) 2017-11-20 2023-12-26 Compass Therapeutics Llc CD137 antibodies and tumor antigen-targeting antibodies and uses thereof
WO2019139388A1 (ko) * 2018-01-10 2019-07-18 보령제약 주식회사 Pi3 키나아제 억제제 및 면역관문 억제제를 포함하는 암의 예방 또는 치료용 약학적 조성물
CA3104218A1 (en) * 2018-06-25 2020-01-02 Immodulon Therapeutics Limited Cancer therapy
US11046769B2 (en) 2018-11-13 2021-06-29 Compass Therapeutics Llc Multispecific binding constructs against checkpoint molecules and uses thereof
WO2022040365A1 (en) * 2020-08-18 2022-02-24 Curators Of The University Of Missouri Compositions and methods of treatment comprising tumor-targeting bacteria and chemotherapy or immunotherapy agent
WO2023091747A1 (en) * 2021-11-22 2023-05-25 Axial Therapeutics, Inc. Modulator compounds, pharmaceutical compositions and uses thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5235033A (en) 1985-03-15 1993-08-10 Anti-Gene Development Group Alpha-morpholino ribonucleoside derivatives and polymers thereof
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
US5270163A (en) 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
RU2001128165A (ru) 1999-03-18 2004-03-27 Эксикон А/С (Dk) Выявление мутаций в генах посредством специфичных lna-праймеров
DK1620544T3 (en) 2003-04-17 2019-01-14 Alnylam Pharmaceuticals Inc MODIFIED iRNA AGENTS
US20050182005A1 (en) 2004-02-13 2005-08-18 Tuschl Thomas H. Anti-microRNA oligonucleotide molecules
JP2008500039A (ja) 2004-05-26 2008-01-10 ロゼッタ ジノミクス リミテッド ウイルスｍｉＲＮＡおよびウイルス関連ｍｉＲＮＡならびにその使用
WO2006126040A1 (en) 2005-05-25 2006-11-30 Rosetta Genomics Ltd. Bacterial and bacterial associated mirnas and uses thereof
CN113967253A (zh) * 2012-05-15 2022-01-25 百时美施贵宝公司 通过破坏pd-1/pd-l1信号传输的免疫治疗
SG10201802061TA (en) * 2013-09-25 2018-05-30 Vertex Pharma A selective inhibitor of phosphatidylinositol 3-kinase-gamma
CA2944903A1 (en) * 2014-04-24 2015-10-29 Dana-Farber Cancer Institute, Inc. Tumor suppressor and oncogene biomarkers predictive of anti-immune checkpoint inhibitor response
US10881732B2 (en) * 2015-06-01 2021-01-05 Maine Medical Center Research Institute Enhancing the therapeutic activity of an immune checkpoint inhibitor
US9861621B2 (en) * 2015-06-29 2018-01-09 Biomed Valley Discoveries, Inc. LPT-723 and immune checkpoint inhibitor combinations and methods of treatment
JP2018522887A (ja) * 2015-07-14 2018-08-16 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 免疫チェックポイント阻害剤を使用する癌の処置法
JO3620B1 (ar) * 2015-08-05 2020-08-27 Amgen Res Munich Gmbh مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم
US20170129911A1 (en) * 2015-11-10 2017-05-11 Massachusetts Institute Of Technology Complexes comprising a platinum compound and an immune checkpoint inhibitor and related methods

Also Published As

Publication number Publication date
US20200323831A1 (en) 2020-10-15
US20200078342A1 (en) 2020-03-12
US20170007587A1 (en) 2017-01-12
US11033537B2 (en) 2021-06-15
JP6786529B2 (ja) 2020-11-18
JP2018519324A (ja) 2018-07-19
JP2022058714A (ja) 2022-04-12
EP3313186A1 (en) 2018-05-02
US10716782B2 (en) 2020-07-21
JP2021004245A (ja) 2021-01-14
US20180117020A1 (en) 2018-05-03
EP3313186A4 (en) 2019-04-03
US9861621B2 (en) 2018-01-09
JP7054547B2 (ja) 2022-04-14
WO2017004079A1 (en) 2017-01-05
US10485796B2 (en) 2019-11-26
JP2023120391A (ja) 2023-08-29

Similar Documents

Publication Publication Date Title
HK1254954A1 (zh) Lpt-723和免疫检查点抑制剂组合物及其治疗方法
JOP20180039A1 (ar) مثبطات pd-1/pd-l1
HK1246286A1 (zh) Lrrk2抑制剂及其制备和使用方法
TW201613887A (en) Antiproliferative compounds and methods of use thereof
HK1258570A1 (zh) 使用dna损伤剂及atr抑制剂的组合治疗癌症的方法
MY199705A (en) Heterocyclic compounds as immunomodulators
MY202022A (en) Pyrrolotriazine compounds as tam inhibitors
MX2018000396A (es) Compuestos aza sustituidos como inhibidores de cinasa 4 asociada al receptor de interleucina 1 (irak-4).
WO2016044189A8 (en) Methods of treating cancer using pd-1 axis binding antagonists and il-17 binding antagonists
MX2018006207A (es) Compuestos heterociclicos como inmunomoduladores.
WO2015168466A8 (en) Inhibitors of lysine specific demethylase-1
WO2017075629A3 (en) Wee 1 kinase inhibitors and methods of making and using the same
MA39986A (fr) Dérivés de purine en tant qu'inhibiteurs de cd73 pour le traitement du cancer
MY193818A (en) Triazole agonists of the apj receptor
MY192703A (en) Compositions containing tucaresol or its analogs
WO2016133903A3 (en) Combination therapy for cancer treatment
WO2015095834A3 (en) Cancer treatments using erk1/2 and bcl-2 family inhibitors
MX382162B (es) Combinaciones farmacéuticas de un inhibidor de enzima hdac con un inhibidor de proteasoma, y su uso en el tratamiento de cáncer.
WO2014150925A3 (en) Deuterated palbociclib
EP4289820A3 (en) Compounds for use in treating alzheimer's disease in apoe4+/+ patients
PH12016502353A1 (en) Pharmaceutical composition
WO2012158672A3 (en) Compounds for use in treatment of mucositis
EA201692481A1 (ru) Комбинация, содержащая глюкокортикоид и edo-s101
WO2015171558A3 (en) BENZENESULFONAMIDO AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORγ AND THE TREATEMENT OF DISEASE
MY202127A (en) Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder